Testing effectiveness (Phase 2)Looking for participantsNCT03093116
What this trial is testing
Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Turning Point Therapeutics, Inc. 500